Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
PHASE2
Total Enrollment
75 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-12-10
Study Completion Date
2021-12-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Since the onset of the disease, more than 40.5 million people have been diagnosed with COVID-19 and nearly 1.2 million people have died (October 21, 2020). There is no complete understanding of the pathogenesis of SARS-CoV-2 infection and to this day there is no specific therapy or vaccine available. Thus, patient care is based on symptomatic therapy and treatment of complications.
Ivermectin has been used for more than 30 years for the treatment of several diseases. More than one million doses of the drug are administered daily, particularly in low- and middle-income countries. Due to the low prevalence of adverse events with the use of this drug, ivermectin is considered to have a good safety profile and its potential benefit in other diseases is currently under investigation.
An in vitro study of ivermectin in SARS-CoV-2 in Australia showed a significant reduction of viral load in infected cells. Subsequently, a descriptive study of 704 critical patients with COVID-19 showed a reduction in mortality, hospitalization, and intensive care unit length-of-stay in those patients who received the drug. Unfortunately, this study was withdrawn by its authors, leaving more questions than answers.
Some countries in Latin America have authorized its use for the management of patients with COVID-19 even in the absence of solid evidence, and several other countries are conducting clinical trials to evaluate its efficacy for the treatment of moderate and severe disease.
Since there is no specific treatment for COVID-19 and the therapeutic options are scarce, the researchers believe it is completely plausible, urgent, and necessary to evaluate if ivermectin use reduces the risk of admission to an intensive care unit (ICU) in hospitalized adults with severe COVID-19. The proposal is a randomized, double-blind clinical trial, conducted at CES Clinic, Medellin-Colombia. The investigators will randomize 100 patients with severe, non-critical illness, into two groups, one group will receive ivermectin in addition to standard management and the other group will receive placebo plus standard management. Clinical outcomes to evaluate will be ICU admission, need for mechanical ventilation, length of hospital stay, days in the ICU and mechanical ventilation, and finally, the incidence of adverse events related to the intervention. The estimated time to complete the study is approximately five months.
Ivermectin has been used for more than 30 years for the treatment of several diseases. More than one million doses of the drug are administered daily, particularly in low- and middle-income countries. Due to the low prevalence of adverse events with the use of this drug, ivermectin is considered to have a good safety profile and its potential benefit in other diseases is currently under investigation.
An in vitro study of ivermectin in SARS-CoV-2 in Australia showed a significant reduction of viral load in infected cells. Subsequently, a descriptive study of 704 critical patients with COVID-19 showed a reduction in mortality, hospitalization, and intensive care unit length-of-stay in those patients who received the drug. Unfortunately, this study was withdrawn by its authors, leaving more questions than answers.
Some countries in Latin America have authorized its use for the management of patients with COVID-19 even in the absence of solid evidence, and several other countries are conducting clinical trials to evaluate its efficacy for the treatment of moderate and severe disease.
Since there is no specific treatment for COVID-19 and the therapeutic options are scarce, the researchers believe it is completely plausible, urgent, and necessary to evaluate if ivermectin use reduces the risk of admission to an intensive care unit (ICU) in hospitalized adults with severe COVID-19. The proposal is a randomized, double-blind clinical trial, conducted at CES Clinic, Medellin-Colombia. The investigators will randomize 100 patients with severe, non-critical illness, into two groups, one group will receive ivermectin in addition to standard management and the other group will receive placebo plus standard management. Clinical outcomes to evaluate will be ICU admission, need for mechanical ventilation, length of hospital stay, days in the ICU and mechanical ventilation, and finally, the incidence of adverse events related to the intervention. The estimated time to complete the study is approximately five months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms
NCT04407507
COVID-19
COMPLETED
PHASE2
Efficacy of Ivermectin in Outpatients With Non-severe COVID-19
NCT04834115
Covid19
Coronavirus Infection
UNKNOWN
PHASE3
COVidIVERmectin: Ivermectin for Treatment of Covid-19
NCT04438850
Covid19
TERMINATED
PHASE2
Outpatient Use of Ivermectin in COVID-19
NCT04530474
Covid19
WITHDRAWN
PHASE3
Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19
NCT04429711
COVID-19
UNKNOWN
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Covid19
Severe Acute Respiratory Syndrome
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Arm #1: 50 patients with routine care offered in the hospital plus ivermectin 400 µg/kg orally in a single dose.
Arm #2: 50 patients with routine care offered in the hospital plus placebo in a single dose.
Arm #2: 50 patients with routine care offered in the hospital plus placebo in a single dose.
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Once the participant consents, staff will collect relevant demographic and clinical data from the clinical chart and a consecutive code from 001 to 100 will be assigned to each in order of arrival. 100 vials of ivermectin or placebo will be stored in the pharmaceutical service with a randomly assigned number from 001 to 100. After placement of medical order, the qualified nursing staff will dispense ivermectin or placebo. Blinded study physicians will carry on daily medical evaluation. Neither the researchers collecting data nor the analyzers will be aware of the patients' treatment arm.
To achieve blinding, a certified pharmaceutical laboratory produced a placebo identical in color, physical form, sensory perception (appearance, smell, and taste), packaging, and labeling to ivermectin.
To achieve blinding, a certified pharmaceutical laboratory produced a placebo identical in color, physical form, sensory perception (appearance, smell, and taste), packaging, and labeling to ivermectin.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention
50 patients with the routine care offered in the hospital plus ivermectin 400 µg/kg (2 drops per kg) orally in a single dose.
Group Type
EXPERIMENTAL
Ivermectin
Intervention Type
DRUG
Routinary care offered in the hospital plus ivermectin 400 µg/kg (2 drops per kg) orally in a single dose.
Control
50 patients with routine care offered in the hospital plus placebo orally (2 drops per kg) in a single dose.
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
OTHER
Routinary care offered in the hospital plus placebo (2 drops per kg) orally in a single dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ivermectin
Routinary care offered in the hospital plus ivermectin 400 µg/kg (2 drops per kg) orally in a single dose.
Intervention Type
DRUG
Placebo
Routinary care offered in the hospital plus placebo (2 drops per kg) orally in a single dose
Intervention Type
OTHER
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Intervention
Control
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Over 18 years old.
* Confirmed diagnosis of SARS-CoV-2 by polymerase chain reaction (PCR).
* Diagnosis of severe pneumonia according to criteria of the National Institute of Health and the Colombian Consensus (suspected respiratory infection, organ failure, arterial oxygen saturation (SaO2) ambient air \<90% or respiratory rate \> 30 resp/min) or diagnosis of acute respiratory distress syndrome according to criteria of the National Institute of Health and the Colombian Consensus (clinical findings, bilateral radiographic infiltrates, + oxygenation deficit as well: mild: 200 mmHg \< PaO2/FiO2 (fraction of inspired oxygen) \< 300 mm/Hg; moderate: 100 mm/Hg \< PaO2/FiO2 \< 200 mm/Hg and, severe: PaO2/FiO2 \< 100 mm/Hg).
* Less than 14 days since the onset of symptoms.
* Hospitalized in a general internal medicine ward, special care unit, or those designated for managing patients with COVID19.
* Confirmed diagnosis of SARS-CoV-2 by polymerase chain reaction (PCR).
* Diagnosis of severe pneumonia according to criteria of the National Institute of Health and the Colombian Consensus (suspected respiratory infection, organ failure, arterial oxygen saturation (SaO2) ambient air \<90% or respiratory rate \> 30 resp/min) or diagnosis of acute respiratory distress syndrome according to criteria of the National Institute of Health and the Colombian Consensus (clinical findings, bilateral radiographic infiltrates, + oxygenation deficit as well: mild: 200 mmHg \< PaO2/FiO2 (fraction of inspired oxygen) \< 300 mm/Hg; moderate: 100 mm/Hg \< PaO2/FiO2 \< 200 mm/Hg and, severe: PaO2/FiO2 \< 100 mm/Hg).
* Less than 14 days since the onset of symptoms.
* Hospitalized in a general internal medicine ward, special care unit, or those designated for managing patients with COVID19.
Exclusion Criteria
* Pregnant or lactating women.
* Use of ivermectin in the two weeks before admission to the clinic
* Diseases affecting the blood-brain barrier (meningitis, encephalocranial trauma, acute subarachnoid hemorrhage)
* Limitation to understanding the explanations and giving consent, defined by the investigating physician.
* Patients with HIV/AIDS
* That the patient is participating in another clinical trial.
* Use of ivermectin in the two weeks before admission to the clinic
* Diseases affecting the blood-brain barrier (meningitis, encephalocranial trauma, acute subarachnoid hemorrhage)
* Limitation to understanding the explanations and giving consent, defined by the investigating physician.
* Patients with HIV/AIDS
* That the patient is participating in another clinical trial.
Minimum Eligible Age
18 Years
Maximum Eligible Age
100 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CES University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Francisco Luis Ochoa-Jaramillo, MD
Principal Investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Francisco L Ochoa-Jaramillo, MD; MSc
Role: PRINCIPAL_INVESTIGATOR
CES University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinica CES
Medellín, Antioquia, Colombia
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Colombia
References
Explore related publications, articles, or registry entries linked to this study.
He F, Deng Y, Li W. Coronavirus disease 2019: What we know? J Med Virol. 2020 Jul;92(7):719-725. doi: 10.1002/jmv.25766. Epub 2020 Mar 28.
Reference Type
BACKGROUND
Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151. doi: 10.3760/cma.j.issn.0254-6450.2020.02.003. Chinese.
Reference Type
BACKGROUND
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
Reference Type
BACKGROUND
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
Reference Type
BACKGROUND
Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). 2023 Aug 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK554776/
Reference Type
BACKGROUND
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.
Reference Type
BACKGROUND
Wang N, Shang J, Jiang S, Du L. Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses. Front Microbiol. 2020 Feb 28;11:298. doi: 10.3389/fmicb.2020.00298. eCollection 2020.
Reference Type
BACKGROUND
Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, Lee M. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020 Apr 28;323(16):1612-1614. doi: 10.1001/jama.2020.4326.
Reference Type
BACKGROUND
Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol. 2020 May;92(5):479-490. doi: 10.1002/jmv.25707. Epub 2020 Mar 3.
Reference Type
BACKGROUND
Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020 Apr;26(4):450-452. doi: 10.1038/s41591-020-0820-9. No abstract available.
Reference Type
BACKGROUND
Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, Chen H, Ding X, Zhao H, Zhang H, Wang C, Zhao J, Sun X, Tian R, Wu W, Wu D, Ma J, Chen Y, Zhang D, Xie J, Yan X, Zhou X, Liu Z, Wang J, Du B, Qin Y, Gao P, Qin X, Xu Y, Zhang W, Li T, Zhang F, Zhao Y, Li Y, Zhang S. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020 Apr 23;382(17):e38. doi: 10.1056/NEJMc2007575. Epub 2020 Apr 8.
Reference Type
BACKGROUND
Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, Edwards KM, Gandhi R, Muller WJ, O'Horo JC, Shoham S, Murad MH, Mustafa RA, Sultan S, Falck-Ytter Y. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis. 2020 Apr 27:ciaa478. doi: 10.1093/cid/ciaa478. Online ahead of print.
Reference Type
BACKGROUND
Hanson KE, Caliendo AM, Arias CA, Englund JA, Lee MJ, Loeb M, Patel R, El Alayli A, Kalot MA, Falck-Ytter Y, Lavergne V, Morgan RL, Murad MH, Sultan S, Bhimraj A, Mustafa RA. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19. Clin Infect Dis. 2020 Jun 16:ciaa760. doi: 10.1093/cid/ciaa760. Online ahead of print.
Reference Type
BACKGROUND
Chen W, Lan Y, Yuan X, Deng X, Li Y, Cai X, Li L, He R, Tan Y, Deng X, Gao M, Tang G, Zhao L, Wang J, Fan Q, Wen C, Tong Y, Tang Y, Hu F, Li F, Tang X. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. Emerg Microbes Infect. 2020 Feb 26;9(1):469-473. doi: 10.1080/22221751.2020.1732837. eCollection 2020.
Reference Type
BACKGROUND
Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, Greninger AL, Pipavath S, Wurfel MM, Evans L, Kritek PA, West TE, Luks A, Gerbino A, Dale CR, Goldman JD, O'Mahony S, Mikacenic C. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. N Engl J Med. 2020 May 21;382(21):2012-2022. doi: 10.1056/NEJMoa2004500. Epub 2020 Mar 30.
Reference Type
BACKGROUND
Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a specific inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J. 2012 May 1;443(3):851-6. doi: 10.1042/BJ20120150.
Reference Type
BACKGROUND
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648. No abstract available.
Reference Type
BACKGROUND
Navarro M, Camprubi D, Requena-Mendez A, Buonfrate D, Giorli G, Kamgno J, Gardon J, Boussinesq M, Munoz J, Krolewiecki A. Safety of high-dose ivermectin: a systematic review and meta-analysis. J Antimicrob Chemother. 2020 Apr 1;75(4):827-834. doi: 10.1093/jac/dkz524.
Reference Type
BACKGROUND
Moseley GW, Filmer RP, DeJesus MA, Jans DA. Nucleocytoplasmic distribution of rabies virus P-protein is regulated by phosphorylation adjacent to C-terminal nuclear import and export signals. Biochemistry. 2007 Oct 30;46(43):12053-61. doi: 10.1021/bi700521m. Epub 2007 Oct 9.
Reference Type
BACKGROUND
Azeem S, Ashraf M, Rasheed MA, Anjum AA, Hameed R. Evaluation of cytotoxicity and antiviral activity of ivermectin against Newcastle disease virus. Pak J Pharm Sci. 2015 Mar;28(2):597-602.
Reference Type
BACKGROUND
Pryor MJ, Rawlinson SM, Butcher RE, Barton CL, Waterhouse TA, Vasudevan SG, Bardin PG, Wright PJ, Jans DA, Davidson AD. Nuclear localization of dengue virus nonstructural protein 5 through its importin alpha/beta-recognized nuclear localization sequences is integral to viral infection. Traffic. 2007 Jul;8(7):795-807. doi: 10.1111/j.1600-0854.2007.00579.x. Epub 2007 May 30.
Reference Type
BACKGROUND
Molinari G, Soloneski S, Reigosa MA, Larramendy ML. In vitro genotoxic and cytotoxic effects of ivermectin and its formulation ivomec on Chinese hamster ovary (CHOK1) cells. J Hazard Mater. 2009 Jun 15;165(1-3):1074-82. doi: 10.1016/j.jhazmat.2008.10.083. Epub 2008 Oct 31.
Reference Type
BACKGROUND
Gonzalez Canga A, Sahagun Prieto AM, Jose Diez Liebana M, Martinez NF, Vega MS, Vieitez JJ. The pharmacokinetics and metabolism of ivermectin in domestic animal species. Vet J. 2009 Jan;179(1):25-37. doi: 10.1016/j.tvjl.2007.07.011. Epub 2007 Sep 11.
Reference Type
BACKGROUND
Gardon J, Gardon-Wendel N, Demanga-Ngangue, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet. 1997 Jul 5;350(9070):18-22. doi: 10.1016/S0140-6736(96)11094-1.
Reference Type
BACKGROUND
Siddiqui AJ, Jahan S, Ashraf SA, Alreshidi M, Ashraf MS, Patel M, Snoussi M, Singh R, Adnan M. Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2. J Biomol Struct Dyn. 2021 Oct;39(17):6828-6841. doi: 10.1080/07391102.2020.1802345. Epub 2020 Aug 5.
Reference Type
BACKGROUND
Portmann-Baracco A, Bryce-Alberti M, Accinelli RA. Antiviral and Anti-Inflammatory Properties of Ivermectin and Its Potential Use in COVID-19. Arch Bronconeumol (Engl Ed). 2020 Dec;56(12):831. doi: 10.1016/j.arbres.2020.06.011. Epub 2020 Jul 7. No abstract available. English, Spanish.
Reference Type
BACKGROUND
Lovato ECW, Barboza LN, Wietzikoski S, de Souza ANV, Auth PA, Junior AG, Dos Reis Livero FA. Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). Curr Pharm Des. 2021;27(1):115-126. doi: 10.2174/1381612826666200707121636.
Reference Type
BACKGROUND
Drozdzal S, Rosik J, Lechowicz K, Machaj F, Kotfis K, Ghavami S, Los MJ. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug Resist Updat. 2020 Dec;53:100719. doi: 10.1016/j.drup.2020.100719. Epub 2020 Jul 15.
Reference Type
BACKGROUND
Wang Z, Yang L. Turning the Tide: Natural Products and Natural-Product-Inspired Chemicals as Potential Counters to SARS-CoV-2 Infection. Front Pharmacol. 2020 Jul 2;11:1013. doi: 10.3389/fphar.2020.01013. eCollection 2020.
Reference Type
BACKGROUND
Gupta D, Sahoo AK, Singh A. Ivermectin: potential candidate for the treatment of Covid 19. Braz J Infect Dis. 2020 Jul-Aug;24(4):369-371. doi: 10.1016/j.bjid.2020.06.002. Epub 2020 Jun 28. No abstract available.
Reference Type
BACKGROUND
Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot (Tokyo). 2020 Sep;73(9):593-602. doi: 10.1038/s41429-020-0336-z. Epub 2020 Jun 12.
Reference Type
BACKGROUND
Chaccour C, Ruiz-Castillo P, Richardson MA, Moncunill G, Casellas A, Carmona-Torre F, Giraldez M, Mota JS, Yuste JR, Azanza JR, Fernandez M, Reina G, Dobano C, Brew J, Sadaba B, Hammann F, Rabinovich R. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial. Trials. 2020 Jun 8;21(1):498. doi: 10.1186/s13063-020-04421-z.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ECA-COVID-CES
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Ivermectin In Treatment of COVID 19 Patients
NCT04425707
UNKNOWN
NA
A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19
NCT04431466
TERMINATED
PHASE2
Clinical Trial to "Study the Efficacy and Therapeutic Safety of Ivermectin: (SAINTBO)
NCT04836299
UNKNOWN
PHASE2
Efficacy of Ivermectin in COVID-19
NCT04392713
UNKNOWN
NA
Ivermectin With Favipiravir in Mild-to-moderate COVID-19 Patients
NCT05155527
UNKNOWN
PHASE2
Ivermectin Treatment Efficacy in Covid-19 High Risk Patients
NCT04920942
COMPLETED
PHASE3
The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment
NCT04351347
RECRUITING
PHASE2/PHASE3
Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial)
NCT04405843
COMPLETED
PHASE2/PHASE3
Evaluation of the Impact of the Administration of Single Dose of Ivermectin in the Early Phase of COVID-19
NCT05040724
UNKNOWN
PHASE3
Study in COvid-19 Patients With iveRmectin (CORVETTE-01)
NCT04703205
UNKNOWN
PHASE2
Inhaled Ivermectin and COVID-19
NCT04681053
UNKNOWN
PHASE3
Ivermectin Versus Standard Treatment in Mild COVID-19
NCT04937569
UNKNOWN
PHASE3
Ivermectin for Post Exposure Prophylaxis of Covid-19
NCT05231603
TERMINATED
PHASE3
Role of Ivermectin and Colchicine in Treatment of COVID-19: Randomized Controlled Clinical Trial
NCT05930002
COMPLETED
NA
A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention
NCT05305560
COMPLETED
PHASE2
Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19
NCT04381884
COMPLETED
PHASE2
Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19
NCT05045937
UNKNOWN
Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19
NCT04632706
COMPLETED
PHASE1
Safety & Efficacy of Low Dose Aspirin / Ivermectin Combination Therapy for Treatment of Covid-19 Patients
NCT04768179
UNKNOWN
PHASE2/PHASE3
Remdesivir- Ivermectin Combination Therapy in Severe Covid-19
NCT04944082
UNKNOWN
PHASE4
A Trial of Remdesivir in Adults With Severe COVID-19
NCT04257656
TERMINATED
PHASE3
Ivermectin to Prevent Hospitalizations in COVID-19
NCT04529525
COMPLETED
PHASE2/PHASE3
Ivermectin Role in Covid-19 Clinical Trial
NCT04746365
COMPLETED
PHASE4
New Antiviral Drugs for Treatment of COVID-19
NCT04392427
UNKNOWN
PHASE3
Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients
NCT04591600
COMPLETED
PHASE1/PHASE2